An infection preventionist is informed that there is a possible cluster of streptococcal meningitis in the neonatal intensive care unit. Which of the following streptococcal serogroops is MOST commonly associated with meningitis in neonates beyond one week of age?
Correct Answer: B
Group B Streptococcus (Streptococcus agalactiae) is the most common cause of neonatal bacterial meningitis beyond one week of age. Step-by-Step Justification: * Group B Streptococcus (GBS) and Neonatal Infections: * GBS is a leading cause of late-onset neonatal meningitis (occurring after 7 days of age). * Infection typically occurs through vertical transmission from the mother or postnatal exposure. * Neonatal Risk Factors: * Premature birth, prolonged rupture of membranes, and maternal GBS colonization increase risk. Why Other Options Are Incorrect: * A. Group A: Rare in neonates and more commonly associated with pharyngitis and skin infections. * C. Group C: Typically associated with animal infections and rarely affects humans. * D. Group D: Includes Enterococcus, which can cause neonatal infections but is not the most common cause of meningitis. CBIC Infection Control References: * APIC Text, "Group B Streptococcus and Neonatal Meningitis".
Question 62
An infection preventionist is evaluating a new catheter that may decrease the rate of catheter-associated urinary tract infections. Which of the following provides the BEST information to support the selection of this catheter?
Correct Answer: D
The correct answer is D, "Cost benefit analysis and safety considerations," as this provides the best information to support the selection of a new catheter aimed at decreasing the rate of catheter-associated urinary tract infections (CAUTIs). According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, selecting medical devices like catheters for infection prevention involves a comprehensive evaluation that balances efficacy, safety, and economic impact. A cost-benefit analysis assesses the financial implications (e.g., reduced infection rates leading to lower treatment costs) against the cost of the new catheter, while safety considerations ensure the device minimizes patient risk, such as reducing biofilm formation or irritation that contributes to CAUTIs (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). This dual focus provides evidence-based data to justify the catheter's adoption, aligning with the goal of improving patient outcomes and reducing healthcare-associated infections (HAIs). Option A (staff member preference and product availability) is subjective and logistical rather than evidence- based, making it insufficient for a decision that impacts infection rates. Option B (product materials and vendor information) offers technical details but lacks the broader context of efficacy and cost-effectiveness needed for a comprehensive evaluation. Option C (value analysis and information provided by the manufacturer) includes a structured assessment of value, but it may be biased toward the manufacturer's claims and lacks the independent safety and cost-benefit perspective critical for infection prevention decisions. The emphasis on cost-benefit analysis and safety considerations reflects CBIC's priority on using data-driven and patient-centered approaches to select interventions that enhance infection control (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 - Use data to guide infection prevention and control strategies). This approach ensures the catheter's selection is supported by robust evidence, optimizing both clinical and economic outcomes in the prevention of CAUTIs. References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 - Use data to guide infection prevention and control strategies; Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment.
Question 63
Following recent renovations on an oncology unit, three patients were identified with Aspergillus infections. The infections were thought to be facility-acquired. Appropriate environmental microbiological monitoring would be to culture the:
Correct Answer: A
The scenario describes an outbreak of Aspergillus infections among three patients on an oncology unit following recent renovations, with the infections suspected to be facility-acquired. Aspergillus is a mold commonly associated with environmental sources, particularly airborne spores, and its presence in immunocompromised patients (e.g., oncology patients) poses a significant risk. The infection preventionist must identify the appropriate environmental microbiological monitoring strategy, guided by the Certification Board of Infection Control and Epidemiology (CBIC) and CDC recommendations. Let's evaluate each option: * A. Air: Aspergillus species are ubiquitous molds that thrive in soil, decaying vegetation, and construction dust, and they are primarily transmitted via airborne spores. Renovations can disturb these spores, leading to aerosolization and inhalation by vulnerable patients. Culturing the air using methods such as settle plates, air samplers, or high-efficiency particulate air (HEPA) filtration monitoring is a standard practice to detect Aspergillus during construction or post-renovation in healthcare settings, especially oncology units where patients are at high risk for invasive aspergillosis. This aligns with CBIC's emphasis on environmental monitoring for airborne pathogens, making it the most appropriate choice. * B. Ice: Ice can be a source of contamination with bacteria (e.g., Pseudomonas, Legionella) or other pathogens if improperly handled or stored, but it is not a typical reservoir for Aspergillus, which is a mold requiring organic material and moisture for growth. While ice safety is important in infection control, culturing ice is irrelevant to an Aspergillus outbreak linked to renovations and is not a priority in this context. * C. Carpet: Carpets can harbor dust, mold, and other microorganisms, especially in high-traffic or poorly maintained areas. Aspergillus spores could theoretically settle in carpet during renovations, but carpets are not a primary source of airborne transmission unless disturbed (e.g., vacuuming). Culturing carpet might be a secondary step if air sampling indicates widespread contamination, but it is less direct and less commonly recommended as the initial monitoring site compared to air sampling. * D. Aerators: Aerators (e.g., faucet aerators) can harbor waterborne pathogens like Pseudomonas or Legionella due to biofilm formation, but Aspergillus is not typically associated with water systems unless there is significant organic contamination or aerosolization from water sources (e.g., cooling towers). Culturing aerators is relevant for waterborne outbreaks, not for an Aspergillus outbreak linked to renovations, making this option inappropriate. The best answer is A, culturing the air, as Aspergillus is an airborne pathogen, and renovations are a known risk factor for spore dispersal in healthcare settings. This monitoring strategy allows the infection preventionist to confirm the source, assess the extent of contamination, and implement control measures (e.g., enhanced filtration, construction barriers) to protect patients. This is consistent with CBIC and CDC guidelines for managing fungal outbreaks in high-risk units. References: * CBIC Infection Prevention and Control (IPC) Core Competency Model (updated 2023), Domain IV: Environment of Care, which recommends air sampling for Aspergillus during construction-related outbreaks. * CBIC Examination Content Outline, Domain III: Prevention and Control of Infectious Diseases, which includes environmental monitoring for facility-acquired infections. * CDC Guidelines for Environmental Infection Control in Healthcare Facilities (2022), which advocate air culturing to detect Aspergillus post-renovation in immunocompromised patient areas.
Question 64
Which of the following statements is true about the microbial activity of chlorhexidine soap?
Correct Answer: D
Chlorhexidine soap is a widely used antiseptic agent in healthcare settings for hand hygiene and skin preparation due to its effective antimicrobial properties. The Certification Board of Infection Control and Epidemiology (CBIC) underscores the importance of proper hand hygiene and antiseptic use in the "Prevention and Control of Infectious Diseases" domain, aligning with guidelines from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Understanding the microbial activity of chlorhexidine is essential for infection preventionists to recommend its appropriate use. Option D, "Persistent activity with a broad spectrum effect," is the true statement. Chlorhexidine exhibits a broad spectrum of activity, meaning it is effective against a wide range of microorganisms, including gram- positive and gram-negative bacteria, some fungi, and certain viruses. Its persistent activity is a key feature, as it binds to the skin and provides a residual antimicrobial effect that continues to inhibit microbial growth for several hours after application. This residual effect is due to chlorhexidine's ability to adhere to the skin's outer layers, releasing slowly over time, which enhances its efficacy in preventing healthcare-associated infections (HAIs). The CDC's "Guideline for Hand Hygiene in Healthcare Settings" (2002) and WHO's "Guidelines on Hand Hygiene in Health Care" (2009) highlight chlorhexidine's prolonged action as a significant advantage over other agents like alcohol. Option A, "As fast as alcohol," is incorrect. Alcohol (e.g., 60-70% isopropyl or ethyl alcohol) acts rapidly by denaturing proteins and disrupting microbial cell membranes, providing immediate kill rates within seconds. Chlorhexidine, while effective, has a slower onset of action, requiring contact times of 15-30 seconds or more to achieve optimal microbial reduction. Its strength lies in persistence rather than speed. Option B, "Can be used with any hand lotion," is false. Chlorhexidine's activity can be diminished or inactivated by certain hand lotions or creams containing anionic compounds (e.g., soaps or moisturizers with high pH), which neutralize its cationic properties. The CDC advises against combining chlorhexidine with incompatible products to maintain its efficacy. Option C, "Poor against gram positive bacteria," is incorrect. Chlorhexidine is highly effective against gram-positive bacteria (e.g., Staphylococcus aureus) and is often more potent against them than against gram-negative bacteria due to differences in cell wall structure, though it still has broad-spectrum activity. The CBIC Practice Analysis (2022) supports the use of evidence-based antiseptics like chlorhexidine, and its persistent, broad-spectrum activity is well-documented in clinical studies (e.g., Larson, 1988, Journal of Hospital Infection). This makes Option D the most accurate statement regarding chlorhexidine soap's microbial activity. References: * CBIC Practice Analysis, 2022. * CDC Guideline for Hand Hygiene in Healthcare Settings, 2002. * WHO Guidelines on Hand Hygiene in Health Care, 2009. * Larson, E. (1988). Guideline for Use of Topical Antimicrobial Agents. Journal of Hospital Infection.
Question 65
Which of the following individuals should be excluded from receiving live attenuated influenza virus?
Correct Answer: A
The correct answer is A, "Pregnant persons," as they should be excluded from receiving the live attenuated influenza virus (LAIV) vaccine. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, which align with recommendations from the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP), the LAIV, commonly known as the nasal spray flu vaccine, contains a live attenuated form of the influenza virus. This vaccine is contraindicated in pregnant individuals due to the theoretical risk of the attenuated virus replicating and potentially harming the fetus, despite limited evidence of adverse outcomes (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.2 - Implement measures to prevent transmission of infectious agents). Pregnant persons are instead recommended to receive the inactivated influenza vaccine (IIV), which is considered safe during pregnancy. Option B (healthy persons aged 2 to 49) is incorrect because this group is generally eligible to receive LAIV, provided they have no other contraindications, as the vaccine is approved for healthy, non-pregnant individuals in this age range (CDC Immunization Schedules, 2024). Option C (persons with allergies to chicken feathers) is not a contraindication for LAIV; the vaccine is produced in eggs, and while egg allergy was historically a concern, current guidelines indicate that LAIV can be administered to persons with egg allergies if they can tolerate egg in their diet, with precautions managed by healthcare providers. Option D (persons simultaneously receiving an inactivated vaccine) is also incorrect, as LAIV can be co-administered with inactivated vaccines without issue, according to ACIP recommendations, as there is no significant interference between the two vaccine types. The exclusion of pregnant persons reflects CBIC's emphasis on tailoring infection prevention strategies, including vaccination programs, to protect vulnerable populations while minimizing risks (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.1 - Collaborate with organizational leaders). This decision is based on precautionary principles outlined in CDC and ACIP guidelines to ensure maternal and fetal safety (CDC Prevention and Control of Seasonal Influenza with Vaccines, 2023). References: CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competencies 3.1 - Collaborate with organizational leaders, 3.2 - Implement measures to prevent transmission of infectious agents. CDC Prevention and Control of Seasonal Influenza with Vaccines, 2023. CDC Immunization Schedules, 2024.
